<DOC>
	<DOCNO>NCT03084757</DOCNO>
	<brief_summary>The study evaluate efficacy target therapy base tumor molecular profile versus conventional chemotherapy patient advance cancer use patient control . This study study involve patient advanced cancer . All type solid tumor allow study .</brief_summary>
	<brief_title>SHIVA02 - Evaluation Efficacy Targeted Therapy Based Tumor Molecular Profiling Patients With Advanced Cancer Using Each Patient Its Own Control</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Inclusion proceed 2 step . First step molecular analyse second step order include efficacy analysis . Inclusion criterion Step 1 : 1 . Patient recurrent/metastatic solid tumor fail candidate treatment usually propose first intention prospective clinical trial indicate tumor board 2 . Patient document progression start conventional therapy accord RECIST 1.1 . 3 . Patient â‰¥18 year old 4 . ECOG performance status 0 1 5 . Measurable disease 6 . Adequate renal function define serum creatinine &lt; 1.5xUNL ( upper normal limit ) 7 . Adequate liver function test define SGOT &amp; SGPT &lt; 3xUNL ( 5xUNL case liver metastasis ) , bilirubin level &lt; 1.5xUNL 8 . Adequate bone marrow function define platelet &gt; 100,000/mm3 , hemoglobin &gt; 9 g/dL , neutrophils &gt; 1,000/mm3 9 . Patient must affiliate French Social Security System 10 . Signed informed consent 11 . For female childbearing potential : negative pregnancy test &lt; 72 hour start study treatment require . If sexually active , female childbearing potential must use `` highly effective '' method contraception study duration 3 month follow last treatment 12 . For male reproductive potential : sexually active male patient must use condom study treatment 3 month follow last treatment Inclusion criterion Step 2 : 1 . Patient Molecular Biology Board ( MBB ) identify druggable molecular alteration RAF/MEK signal pathway treatment recommendation establish MBB . 2 . Patient document progression conventional therapy accord RECIST 1.1 . 3 . Patient image perform within 28 day prior plan start date treatment Exclusion criterion : 1 . Patients 18 year old 2 . Patients CNS involvement control &gt; 3 month 3 . Patients plan receive molecularly target agent 4 . Patients candidate receive molecularly target agent approve disease 5 . Patients concurrent severe and/or uncontrolled medical disease could compromise participation study , include uncontrolled diabetes , cardiac disease , uncontrolled hypertension , congestive cardiac failure , ventricular arrhythmia , active ischemic heart disease , myocardial infection within one year , chronic liver renal disease , active gastrointestinal tract ulceration , severely impaired lung function 6 . Pregnant and/or breastfeed woman 7 . Patients individually deprive liberty place authority tutor 8 . Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 9 . Known HIV , HBV , HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>